1. Siemens Healthineers expects tariff impact to "double"
Siemens Healthineers expects that, due to the impact of global trade policies,2026the negative impact of tariffs in the fiscal year will double to4hundred million euros. The company stated that although it faces short-term pressure, its global manufacturing footprint and localization strategy are expected tofully offset the tariff impact over the medium term.CEOIt criticized the current trade disputes for undermining the operational efficiency of globalized companies.
2. Core Medical STAR Market listing application IPO accepted
Following the resumption of the STAR Market's fifth listing standard, the first innovative medical device company——Shenzhen Core MedicalIPOhas been accepted and plans to raise12.17hundred million yuan. The company focuses onartificial heart R&D, and its world's smallest magnetically levitated artificial heartCorheart®6has already taken a leading position in China, and it is also developing products for pediatric use and biventricular heart failure treatment. Although it has not yetbecome profitable, it has receivedinvestment from well-known institutions such as Hillhouse and Legend Capital, highlighting the capital market's recognition of the long-term value of hard-tech innovation.
3. Olympus plans to cut approximately 2000 employees
Olympus announced global layoffs of approximately2000employees as part of its endoscopy business restructuring plan, aimed atenhancing accountability and accelerating innovation and growth. This restructuring is expected to deliver, in2026and2027fiscal years, annualsavings of approximately240hundred million yen（1.566US dollars). The newly appointedCEOBob·White said the company will reduce organizational layers and streamline processes,to driveAI, advanced endoscope development supported by robotics technology and digital ecosystems. In addition, the company has set financial targets to2029 achieve annual revenue growth by fiscal year5% and other financial targets.
4. GEHealthcare issues a Class II recall of patient monitors
GEHealthcare has initiated a Class II recall:Portrait VSMpatient monitors due to certainbattery lots having a risk of reduced charge retention, which may lead todevice power loss, interruption of monitoring, and delayed recognition of patient deterioration. A total of5990 units are affected globally, including across the United States. The company isreplacing the affected batteries free of charge, and advises users to ensure connection to main power and have a backup plan in place before the issue is corrected.
5. Philips issues a Class II recall of medicalXX-ray systems
Philips has initiated a Class II recall: certainRadiography 7300 CmedicalXX-ray systems have a ceiling-suspension assembly that, due to a manufacturing issue, may make manual raising and lowering difficult, requiring additional force. A total of284 units are affected, including in the United States and30 multiple countries and regions. The company advises users to temporarily use the powered lift function and will provide a technical correction as soon as possible.
6. Philips Respironics issues a Class II recall
Philips subsidiaryRespironics has initiated a Class II recall:56 units ofSimplyGo Ministandard battery packs for portable oxygen concentrators due to a chip defect, which may cause sudden power loss during operation and interruption of oxygen delivery. The affected products were distributed across multiple U.S. states and Canada. Users should stop using them immediately and verify the serial number; if affected, they should contact the distributor for replacement.
7. CIIE: Medical device leaders focus on chronic disease and AI
At the 8th CIIE, pharmaceutical and medical device leaders focused on chronic disease prevention and control,AIwith empowerment and ecosystem co-development emerging as the key to breaking through. Novartis, GSK, Bayer, and others showcased innovative solutions for lipid management and herpes zoster prevention; Novo Nordisk partnered with pharmacies to launch“Lightness House”；Boston Scientific, Philips, and MediTrust Health, among others, launchedAImedical platforms. Through R&D collaboration, retail integration, and digital technologies, stakeholders are jointly building an“integrated care-and-prevention and full-spectrum health service”ecosystem.
8. Synchron financing of2hundred-million-dollar funding to advance brain-computer interface commercialization
Brain-computer interface companySynchronannounced that it had completed2hundreds of millions of U.S. dollarsDround of financing,to advance its craniotomy-freeStentrodebrain-computer interface system's pivotal clinical trials and commercialization preparations, and to develop a next-generation high-channel-count whole-brain interface. The round was led byDouble Point Ventureswith participation from multiple new and existing investors,driving2024to2025global brain-computer interface sector financing in10hundreds of millions of U.S. dollars.
9. Announcement on the Renewal of the Medical Electroacoustic Equipment Standardization Committee
The NMPA recently issued an announcement approvingThe technical standardization lead unit for medical electroacoustic devices has completed its reappointment, and announced the composition plan for its second term. This move is intended to strengthen the standards system in this field, promote the high-quality and standardized development of medical electroacoustic devices, and ensure the safety and effectiveness of medical devices.
10.FDAClass I recall of an Android appAPP
U.S.FDAissued a Class I recall:Dexcomthe company because itsG6continuous glucose monitoring system Android appApp（v1.15.0) contains a software defect that may cause the application to terminate unexpectedly, preventing users from receiving glucose alerts and posing a serious health risk. The company has required users to upgrade to the new version by10month6dayApp, and the affected product was distributed in limited quantities within the United States. The recall is still ongoing.
11.FDAClass I recall due to insulin pump software defect
United StatesFDAissued a Class I recall:TandemA diabetes company, due to anMobiinsulin pump software defect, which may cause“Malfunction 12”errors, unexpectedly interrupting insulin delivery and creating a risk of hyperglycemia. The affected products involve over 1.7 units, distributed across the United States50 states. The company has notified users to immediately upgrade to7.9.0.2 software and implement a backup dosing plan.
Follow Clinsota for daily medical device news updates.